Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Kojic acid

Also known as: 5-hydroxy-2-(hydroxymethyl)-4-pyrone

Kojic acid is a compound produced by certain fungi and used in skincare to reduce pigment formation. It acts on tyrosinase, an enzyme involved in making melanin, and appears in cosmetic formulations for uneven pigmentation.

In plain English — Kojic acid is a skincare ingredient that acts on the process that makes skin pigment. Some creams containing it have helped reduce melasma in clinical studies. The whole product matters, including whether it suits the person's skin and causes irritation or allergy.

Evidence status

Moderate

Human melasma studies; formulation-specific findings. Small clinical studies support improvement with some kojic-acid-containing preparations. Their combinations and study limitations constrain ingredient-only conclusions; regulatory safety assessments apply to specified cosmetic uses.

What kojic acid is, and the types available#

Kojic acid is a small compound produced by fungi, including Aspergillus species. Cosmetic products use it for its effect on pigment formation. An ingredient list may instead name a derivative such as kojic dipalmitate; that identifies a different chemical, requiring its own assessment.[1]

The clinical literature includes kojic-acid-only creams and mixtures with other pigment-directed ingredients. Cosmetic preparations and clinician-directed combinations containing medicines require different selection and supply decisions. The hyperpigmentation entry explains the assessment of dark patches; melasma covers that particular condition.[3, 4, 6, 7, 9]i

Use of kojic acid in aesthetic practice#

Its practical role is within product selection for an assessed pigmentation concern. Establish what the colour change represents, the client’s current treatment, previous reactions and the desired appearance outcome. A useful record identifies the actual product and its other actives, so any benefit or reaction can be interpreted in context.[3, 4, 6, 7, 9]i[3, 5, 10]i

For melasma, photoprotection remains part of care. Cosmetic support can sit alongside clinician-led management, with sunscreen and SPF and the condition entry providing the broader context.[9]

Contraindications and cautions#

Known allergy to kojic acid or another constituent means avoiding that preparation. With existing dermatitis, damaged skin or a recent peel, assess the skin state first: the SCCS specifically flags increased absorption through a weakened barrier. Its final favourable cosmetic assessment therefore should not be transferred automatically to freshly injured skin.[1][3, 5, 10]i

This review did not locate human pregnancy or breastfeeding outcome studies establishing topical kojic acid’s safety. That uncertainty is not proof of harm, but it prevents a confident pregnancy-safety assurance. Discuss elective pigment treatment with the person’s maternity or treating clinician rather than treating fungal origin as a safety category.[no source found]

Clinical uses and the evidence behind them#

Facial melasma

Deo and colleagues studied 80 Indian adults aged 18–58 for 12 weeks, with 20 in each of four groups: 1% kojic acid alone, with 2% hydroquinone, with 0.1% betamethasone, or with both. All were provided with sunscreen and advised photoprotection. Participants were blinded; the investigator was not. All groups improved, and the authors favoured the hydroquinone combination. They declared no funding or conflicts. These are trial formulations, not a treatment recipe.[3]

Combination-formulation evidence

A later Thai split-face trial analysed 27 participants, predominantly women with Fitzpatrick types III–IV, after comparing 5% alpha-arbutin/2% kojic acid with triple-combination cream for 12 weeks. Physician-rated improvement favoured triple cream, which caused more stinging and erythema. The authors considered the alternative promising for tolerability; they declared no specific funding or conflicts. Current concentration restrictions are addressed under selection below.[4]

Selecting kojic acid#

Check the full formula, intended application site, product traceability and evidence for the actual concern. A compliant concentration is one part of a product’s safety assessment; it does not establish clinical efficacy. Combination preparations also require consideration of every other active and any relevant medicine-supply requirements.[3, 4, 6, 7, 9]i

As checked in September 2026, Great Britain restricts kojic acid in cosmetics to 1% in face and hand products. Northern Ireland, through its EU-aligned framework, has the same specific concentration/site limit under separate legislation. Both relevant transition periods have ended. The higher-concentration research preparation described above is consequently not a cosmetic formulation to reproduce for these markets.[6][7, 8]

Adverse effects and their management#

Irritation and allergic contact dermatitis are the principal local concerns to recognise. Burning was reported in the Indian trial, and clinical contact-allergy reports exist.[3, 5, 10]i

New itch, redness, cracking, blistering or weeping warrants attention to the whole exposure history. Avoid the suspected trigger; persistent, recurrent or severe dermatitis needs clinical assessment. Formal diagnostic patch testing, where indicated, is a medical investigation rather than proof supplied by a one-off salon product test.[3, 5, 10]i

Referral and scope boundaries#

An uncertain, changing or otherwise concerning pigmented lesion needs medical assessment before cosmetic lightening. A clinician should also review an unresolved dermatitis or a pigmentation problem whose diagnosis or treatment falls outside the practitioner’s competence.[9][3, 5, 10]i

Kojic acid research involving hydroquinone or corticosteroids does not authorise a non-prescriber to construct a medicinal combination. Use the hydroquinone entry for the medicine-specific context and keep decisions about an existing prescription with the treating clinician.[3][9]

Mechanism of action#

Tyrosinase participates in the early reactions that produce melanin. In laboratory work, kojic acid inhibits its activity. Wang and colleagues demonstrated effects using mushroom tyrosinase and mouse B16F10 melanoma cells; these experiments support the biochemical rationale, with human appearance outcomes addressed separately in the clinical studies. The work received Chinese public research grants and declared no conflicts.[2]

For the wider pathway, see melanogenesis. Differences between enzyme systems, cells and finished topical products help explain why mechanism alone cannot supply a clinical effect size.[2]

Commonly misstated claims#

“The enzyme study proves kojic acid is the best pigment ingredient”

Claim heard: A favourable laboratory comparison establishes clinical superiority.

Literature finding:Wang’s conclusion selected a useful positive control for mushroom-enzyme and mouse-cell experiments. It did not compare treatment of human faces.[2]

Supported statement: Kojic acid is a useful experimental tyrosinase inhibitor; clinical selection requires human formulation evidence.

“Most kojic acid users become allergic”

Claim heard: The often-cited five-of-eight finding describes ordinary users.

Literature finding: Those eight women were previously exposed patients within a clinic series of 220 suspected cosmetic-dermatitis referrals. The authors judged sensitising potential high in that selected setting; the later SCCS assessment described overall human occurrence as very low.[1, 5]i

Supported statement: Contact allergy is documented, but that selected denominator cannot estimate general-user risk.

“The combination study proves synergy with hydroquinone”

Claim heard:A better combination result proves the ingredients amplify each other’s effects.

Literature finding:Deo’s favourable interpretation came from four arms that all contained kojic acid; there was no hydroquinone-only comparison.[3]i

Supported statement: The study supports that tested combination, without isolating added benefit over hydroquinone alone or demonstrating formal synergy.

Areas of remaining uncertainty#

  • Durability:Short studies leave maintenance and post-treatment outcomes uncertain. The later trial’s recurrence reporting also contains conflicting statistics; do not promise a durable relapse advantage from it.[3, 4]i
  • Transfer between products:Ingredient mixtures and vehicles differ. Ask for evidence of the finished product before attaching a trial’s result to another formulation.[3, 4, 6, 7, 9]i
  • Derivative performance: The SCCS opinion did not assess kojic esters. Their individual identity and supporting evidence therefore need checking rather than inheritance from kojic acid.[1]

Frequently asked questions#

What is kojic acid mainly used for in skincare?

Uneven pigmentation. Human research discussed here is principally in facial melasma; the diagnosis determines whether pigment-directed skincare is appropriate.[3, 4, 6, 7, 9]i

Does a kojic acid product replace sunscreen?

No. Photoprotection remains part of melasma care, regardless of the chosen pigment ingredient.[9]

What should be recorded when assessing a product?

Its exact identity, full ingredients, intended site, relevant evidence and any reaction history. The selection section explains the current territorial composition limits.[3, 4, 6, 7, 9]i[7, 8]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. SCCS. Opinion on Kojic acid. SCCS/1637/21, final March 2022; corrigendum June 2022.Tier 1Supports: Chemical identity, final cosmetic risk assessment, weakened-barrier caution, human allergy assessment and exclusion of derivatives. Relevant PDF sections read; conclusion rendered.Funding / interest: European Commission scientific committee assessment, including industry-submitted studies. Not a declaration of independence for every underlying experiment.
  2. Wang W, Gao Y, Wang W, et al. Kojic Acid Showed Consistent Inhibitory Activity on Tyrosinase from Mushroom and in Cultured B16F10 Cells Compared with Arbutins. Antioxidants. 2022;11(3):502. doi:10.3390/antiox11030502. PMID:35326152.In vitroTier 3Supports: Mushroom enzyme assays and mouse melanoma-cell findings; authors' laboratory positive-control conclusion, not a clinical ranking.Funding / interest: Chinese Academy of Agricultural Sciences and National Natural Science Foundation of China grants; authors declared no conflicts.
  3. Deo KS, Dash KN, Sharma YK, Virmani NC, Oberai C. Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety. Indian J Dermatol. 2013;58(4):281–285. doi:10.4103/0019-5154.113940. PMID:23918998.Tier 2Supports: Twelve-week facial melasma study in 80 Indian adults, four kojic-containing arms; favourable combination result and design limits. Full XML retrieved.Funding / interest: Authors reported no funding and no conflicts of interest.
  4. Tantanasrigul P, Sripha A, Chongmelaxme B. The Efficacy of Topical Cosmetic Containing Alpha-Arbutin 5% and Kojic Acid 2% Compared With Triple Combination Cream for the Treatment of Melasma: A Split-Face, Evaluator-Blinded Randomized Pilot Study. J Cosmet Dermatol. 2025;24(1):e16562. doi:10.1111/jocd.16562. PMID:39555866.Tier 2Supports: Thai facial melasma trial, 27 analysed, 12 weeks with four-week follow-up; combination efficacy/tolerability and internally inconsistent recurrence reporting. Full XML read.Funding / interest: Authors declared no specific funding and no conflicts of interest.
  5. Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis. 1995;32(1):9–13. doi:10.1111/j.1600-0536.1995.tb00832.x. PMID:7720390.Tier 3Supports: Contact allergy in selected Japanese women referred with suspected cosmetic dermatitis; exposed subgroup denominator, not population incidence. Full abstract retrieved.Funding / interest: Funding and conflicts unavailable in the retrieved abstract.
  6. UK. Cosmetic Products (Restriction of Chemical Substances) (No. 2) Regulations 2024, SI 2024/1334, regulation 3 and schedule 2.Tier 1Supports: GB restriction: kojic acid 1% in face/hand products, annex III entry 323. Official XML and current annex III row retrieved.Funding / interest: Primary GB legislation.
  7. European Commission. Regulation (EU) 2024/996, annex III entry 375 and transition provisions.Tier 1Supports: EU kojic-acid limit of 1% in face/hand products; product-availability transition ended November 2025.Funding / interest: Primary EU legislation.
  8. OPSS. Cosmetics Regulation and enforcement: Northern Ireland. Updated 29 June 2026.Tier 1Supports: Separate NI framework applying EU cosmetics requirements; territorial scope directly retrieved.Funding / interest: UK government statutory guidance.
  9. British Association of Dermatologists. Melasma. Patient information leaflet, June 2024.Tier 4Supports: Clinical assessment, photoprotection, treatment context and medical review of changing pigmented lesions.Funding / interest: Professional-association consensus leaflet; no commercial sponsor stated.
  10. NHS. Contact dermatitis. Reviewed 3 May 2023; accessed 16 September 2026.Tier 4Supports: Recognising contact dermatitis, avoiding triggers and seeking assessment for persistent, recurrent or severe symptoms.Funding / interest: NHS patient information; no page-specific sponsor stated.